Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

Autor: Stephen D. Silberstein, Joshua M. Cohen, Ronghua Yang, Sanjay K. Gandhi, Evelyn Du, Adelene E. Jann, Michael J. Marmura

Publikováno v: The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-11 (2021)

Abstract Background Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, including the fully humanized monoclonal antibody (IgG2Δa) fremanezumab, have demonstrated safety and efficacy for migraine prevention. Clinical

Externí odkaz: https://doaj.org/article/ab5e628345ee4406a72f5bbf76a7d45d

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine

Autor: Sanjay Gandhi, Evelyn Du, Messoud Ashina, Joshua M. Cohen

Publikováno v: Headache
Ashina, M, Cohen, J M, Gandhi, S K & Du, E 2021, ' Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine ', Headache, vol. 61, no. 6, pp. 916-926 . https://doi.org/10.1111/head.14127

Objective To evaluate the impact of fremanezumab on the severity and duration of remaining migraine attacks in patients with chronic migraine (CM) or episodic migraine (EM). Background Fremanezumab is a fully humanized monoclonal antibody (IgGΔa) th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1e130e9042237c3d916417fdf39909b
https://doi.org/10.1111/head.14127

Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

Autor: Michael J. Marmura, Joshua M. Cohen, Evelyn Du, Stephen D. Silberstein, Ronghua Yang, Sanjay K. Gandhi, Adelene E. Jann

Publikováno v: The Journal of Headache and Pain
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-11 (2021)

Background Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, including the fully humanized monoclonal antibody (IgG2Δa) fremanezumab, have demonstrated safety and efficacy for migraine prevention. Clinical trials in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f536de9ce87b4cfbc26bee3a5bf9f721
https://pubmed.ncbi.nlm.nih.gov/33413075

In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV

Autor: J Christian, Virchow, Lisa, Hickey, Evelyn, Du, Margaret, Garin

Publikováno v: Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology

Background A post hoc analysis of two randomized, placebo–controlled, Phase 3 trials of intravenous reslizumab, an anti-interleukin-5 (IL-5) biologic for severe eosinophilic asthma. Methods Relationships between baseline blood eosinophil levels (EO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2f92fac4d72eb32a57177aef997a0b3c
https://pubmed.ncbi.nlm.nih.gov/32328116

Depressed mood and quality of life after subarachnoid hemorrhage

Autor: Brian F. Fitzsimmons, Stephan A. Mayer, E. Sander Connolly, Axel Rosengart, Jan Claassen, Kurt T. Kreiter, Y. Evelyn Du, Shelley Peery

Publikováno v: Journal of the Neurological Sciences. 335:64-71

Background Cognitive impairment is widely considered the main cause of disability and handicap after subarachnoid hemorrhage (SAH). The impact of depression on recovery after SAH remains poorly defined. We sought to determine the frequency of post-SA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a04cb168f6899f38a1490c803ba31e30
https://doi.org/10.1016/j.jns.2013.08.024